KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Retained Earnings (2017 - 2025)

Historic Retained Earnings for Aquestive Therapeutics (AQST) over the last 9 years, with Q3 2025 value amounting to -$415.1 million.

  • Aquestive Therapeutics' Retained Earnings fell 1992.7% to -$415.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$415.1 million, marking a year-over-year decrease of 1992.7%. This contributed to the annual value of -$363.2 million for FY2024, which is 1383.27% down from last year.
  • According to the latest figures from Q3 2025, Aquestive Therapeutics' Retained Earnings is -$415.1 million, which was down 1992.7% from -$399.7 million recorded in Q2 2025.
  • Aquestive Therapeutics' Retained Earnings' 5-year high stood at -$200.9 million during Q1 2021, with a 5-year trough of -$415.1 million in Q3 2025.
  • For the 5-year period, Aquestive Therapeutics' Retained Earnings averaged around -$309.7 million, with its median value being -$311.0 million (2023).
  • As far as peak fluctuations go, Aquestive Therapeutics' Retained Earnings crashed by 4282.77% in 2021, and later plummeted by 252.89% in 2023.
  • Aquestive Therapeutics' Retained Earnings (Quarter) stood at -$256.8 million in 2021, then dropped by 21.19% to -$311.2 million in 2022, then dropped by 2.53% to -$319.1 million in 2023, then decreased by 13.83% to -$363.2 million in 2024, then fell by 14.3% to -$415.1 million in 2025.
  • Its Retained Earnings stands at -$415.1 million for Q3 2025, versus -$399.7 million for Q2 2025 and -$386.1 million for Q1 2025.